All In Biotech

Drug Trial Radar · NCT04666792

PrEParing Family Planning Clinics to Streamline Integration of HIV Prevention Services for Young Women in Kenya

Last checked: Nov 19, 2026Latest source record: Sep 4, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

25,457

Actual

Start

Mar 1, 2021

Primary completion

Dec 31, 2024

Study completion Dec 31, 2024

Sponsor

Lead sponsor
University of WashingtonAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute of Mental Health (NIMH); Kenyatta National Hospital; Kenya National AIDS & STI Control Programme; Kisumu County Government
First posted
Dec 14, 2020

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
Female only
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This a prospective, open-label implementation project to catalyze integration of HIV prevention and PrEP care services for adolescent girls and young women in family planning clinics in Kenya.

Conditions

  • HIV Infections
  • Contraception
  • STI

Interventions

  • PrEPDrug

    A fixed-dose, oral co-formulation of emtricitabine (FTC)/tenofovir disoproxil fumarate (TDF) is the approved and preferred regimen for HIV-1 prevention in Kenya and the United States. The World Health Organization (WHO) recommends TDF-containing medications as PrEP, which includes TDF combined with FTC as well as potentially TDF alone and TDF combined with lamivudine (or 3TC, a medication closely related to FTC). Any TDF-containing medications that align with WHO and Kenya national guidelines for PrEP will be used. PrEP medication will come from clinic stocks.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of women accessing family planning services who are screened for HIV riskTime frame: up to 24 months
  2. Proportion of women accessing family planning services who uptake PrEP for HIV preventionTime frame: up to 24 months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Kenyatta National Hospital

    Kisumu, Kenya

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.